

Date: 18.06.2020

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai - 400 001

Sub: Submission of Audited Standalone and Consolidated Financial Results of the Company along with Auditor's Report as per Provisions of Regulation 33 of SEBI (LODR) Regulations, 2015.

Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

1. Financial Results: Audited Standalone and Consolidated Financial Results along with Auditor's Report of the company for the Fourth Quarter/ Year Ended 31st March, 2020.

This is for your Information and Necessary Records.

Thanking you
For TRIMURTHI LIMITED



Arun Kumar Bhangadia
Managing Director
DIN: 00021024

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

Date: 18.06.2020

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 18/06/2020 as per Regulation 30, 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Thursday, the 18th Day of June, 2020 at Registered Office, have approved and taken on record the following:

1. The Board has considered and approved the minutes of the previous board meeting.
2. The Board has considered and approved the Audited Standalone and Consolidated Financial Results along with Auditor's Report issued by the Statutory Auditors of the Company for the Quarter IV/Year ended 31st March, 2020 in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.
3. The board has considered and approved venturing into the business of manufacture of Gloves, Masks and other surgical and medical consumables other Textile related products, non woven Fabric cloth, etc., in partnership.

There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 03.30 P.M. and Concluded at 04:30 P.M.

Request you to take same on records.

Thanking you

For TRIMURTHI LIMITED

Arun Kumar Bhangadia
Managing Director
DIN: 00021024

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA, | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED
Standalone Statement of Assets and Liabilities

(Amount in Lakhs)



Particulars	Year Ended 31-03-2020	Year Ended 31-03-2019
ASSETS		
1 Non Current Assets		
a Property, Plant and Equipments	30.82	36.86
b Capital Work In Progress	-	-
c Investment Property	-	-
d Goodwill	-	-
e Other Intangible Assets	0.08	0.37
f Intangible Assets under development	-	-
g Biological assets other than bearer plants	-	-
h Financial Assets:		
Investments	352.68	272.16
Trade Receivables	-	-
Loans	-	-
Others	-	-
Loans	-	-
Others	-	-
i Deferred Tax Assets (net)		
Other Non Current Assets	20.00	20.75
	Total Non Current Assets	403.58
		330.14
2 Current Assets		
a Inventories	7.83	10.27
b Financial Assets	-	-
Investments	-	-
Trade Receivables	228.32	213.97
Cash and Cash Equivalents	95.23	16.03
Bank balances other than above	-	-
Loans	367.98	434.46
Others	-	-
c Current Tax Assets (net)	-	-
d Other Current Assets	101.05	208.25
	Total Current Assets	800.40
		882.98
	Total Assets	1,203.98
		1,213.12
EQUITY AND LIABILITIES		
1 Equity		
a Equity Share Capital	810.00	810.00
b Other Equity	397.10	391.04
Total - Equity	1,207.10	1,201.04
2 Liabilities		
Non Current Liabilities		
a Financial Liabilities	-	-
Borrowings	-	-
Trade Payables	-	-
Other Financial Liabilities	-	-
b Provisions	-	-
c Deferred Tax Liabilities (net)	(5.85)	(6.38)
d Other Non Current Liabilities	-	-
	Total Non Current Liabilities	(5.85)
		(6.38)
Current Liabilities		
a Financial Liabilities	-	-
Borrowings	-	-
Trade Payables	0.67	10.38
Other Financial Liabilities	-	-
b Other Current Liabilities	1.42	3.58
c Provisions	-	-
d Current Tax Liabilities (net)	0.64	4.49
	Total Current Liabilities	2.73
		18.45
	Total - Equity and Liabilities	1,203.98
		1,213.12

Place: Hyderabad

Date: 18-06-2020
(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-237/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

For Trimurthi Ltd
Arun Kumar Bhanodia
Managing Director
Din No. 00021024



TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095,
STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER IV AND 12 MONTHS ENDED 31ST MARCH 2020

(Amount in Lakhs except EPS)

PARTICULARS	QUARTER ENDED			YEAR ENDED	
	31.03.2020 (AUDITED)	31.12.2019 (UNAUDITED)	31.03.2019 (AUDITED)	31.03.2020 (AUDITED)	31.03.2019 (AUDITED)
1. INCOME					
INCOME FROM OPERATIONS	51.83	18.34	48.84	103.23	359.19
OTHER INCOME	10.41	11.90	11.14	47.31	13.23
TOTAL INCOME	61.44	30.24	59.98	150.54	372.43
2. EXPENSES					
PURCHASES	24.81	12.94	26.74	73.21	277.05
COST OF MATERIALS CONSUMED					
MANUFACTURING EXPENSES					
WORK IN PROGRESS AND STOCK IN TRADE	(1.43)	2.91	0.17	2.44	0.03
RENT	1.05	0.30	0.75	1.95	3.00
EMPLOYEE BENEFITS EXPENSE	6.90	8.57	8.07	28.30	32.72
FINANCE COSTS	-	-	-	-	-
DEPRECIATION AND AMORTISATION EXPENSES	0.92	2.26	3.34	7.82	12.15
OTHER EXPENSES	9.24	3.69	6.70	26.16	26.39
TOTAL EXPENSES	41.79	31.67	45.77	139.89	353.34
3. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE EXCEPTIONAL ITEMS (1-2)	19.65	(1.42)	14.21	10.65	19.08
4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS					
5. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (3-4)	19.65	(1.42)	14.21	10.65	19.08
6. TAX EXPENSES					
-CURRENT TAX	1.11	0.01	3.52	3.17	(5.92)
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS	0.64	-	3.78	0.64	4.49
-DEFERRED TAX (NET)	0.47	0.01	(0.26)	0.33	(10.40)
7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (5-6)	18.55	(1.43)	10.69	9.48	25.00
8. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS					
9. TAX EXPENSES FOR DISCONTINUED OPERATIONS					
10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)					
11. PROFIT/(LOSS) FOR THE PERIOD (7+10)	18.55	(1.43)	10.69	9.48	25.00
12. OTHER COMPREHENSIVE INCOME					
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS					
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS					
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS					
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	(2.91)	(0.19)	3.92	(3.43)	(6.20)
13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)	16.54	(3.62)	14.61	6.05	18.80
14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION):					
(i) BASIC	0.23	(0.02)	0.13	0.12	0.31
(ii) DILUTED	0.23	(0.02)	0.13	0.12	0.31
15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION):					
(i) BASIC					
(ii) DILUTED					
16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION):					
(i) BASIC	0.23	(0.02)	0.13	0.12	0.31
(ii) DILUTED	0.23	(0.02)	0.13	0.12	0.31

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956



TRIMURTHI LIMITED

SCHEDULE III OF THE COMPANIES ACT 2013

PART-II

PARTICULARS	QUARTER ENDED			YEAR ENDED	
	31.03.2020 (AUDITED)	31.12.2019 (UNAUDITED)	31.03.2019 (AUDITED)	31.03.2020 (AUDITED)	31.03.2019 (AUDITED)
A. PARTICULARS OF SHARE HOLDING					
1. Public Share Holding					
- Number of Shares	2900600	2900600	2900600	2900600	2900600
- Percentage of shareholding	35.81%	35.81%	35.81%	35.81%	35.81%
2. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the shareholding of promoter and promoter group)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
b. Non encumbered					
- No of Equity Shares	5199400	5199400	5199400	5199400	5199400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	64.19%

Particulars	3 Months Ended (31/03/2020)
B. Investor Complaints	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

TRIMURTHI LIMITED

Segment Reporting

PARTICULARS	QUARTER ENDED			YEAR ENDED	
	31.03.2020 (AUDITED)	31.12.2019 (UNAUDITED)	31.03.2019 (AUDITED)	31.03.2020 (AUDITED)	31.03.2019 (AUDITED)
1. Segment Revenue					
a. Pharma Business	-	-	-	-	-
b. Financial Services	10.67	10.80	12.70	42.56	37.64
c. Investments	(0.48)	1.10	11.14	4.53	12.99
d. Trading in Shares	51.25	18.34	0.97	103.45	30.81
e. Foods	-	-	26.17	-	27.99
Total	61.44	30.24	59.97	150.54	372.43
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Net Sales/ Income From Operations	61.44	30.24	59.97	150.54	372.43
2. Segment Profits (Before tax & Interest From Each Segment)					
a. Pharma Business	-	-	-	-	-
b. Financial Services	10.67	10.80	8.76	42.56	45.45
c. Investments	(0.48)	1.10	11.14	4.53	12.99
d. Trading in Shares	9.46	(13.32)	4.81	(36.44)	13.97
e. Foods	-	-	(0.51)	-	(53.33)
Total	19.65	(1.42)	14.21	10.65	19.08
Less:					
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Total Profit Before Tax	19.65	(1.42)	14.21	10.65	19.08
3. Capital Employed					
a. Pharma Business	29.50	29.50	-	29.50	-
b. Financial Services	367.98	369.90	544.22	367.98	544.22
c. Investments	23.18	30.19	272.16	23.18	272.16
d. Trading in Shares	486.44	460.97	372.38	486.44	372.38
e. Foods	300.00	300.00	12.29	300.00	12.29
Total	1,207.10	1,190.56	1,201.04	1,207.10	1,201.04

Notes:

1. Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.

2. The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 18-06-2020.

3. The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

Place : Hyderabad
Date : 18-06-2020

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956



TRIMURTHI LIMITED
Consolidated Statement of Assets and Liabilities

(Amount in Lakhs)

Particulars

**Year Ended
31-03-2020**

**Year Ended
31-03-2019**

**TRIMURTHI
GROUP**

ASSETS

1 Non Current Assets

a Property, Plant and Equipments	177.69	188.66
b Capital Work In Progress	-	-
c Investment Property	-	-
d Goodwill	-	-
e Other Intangible Assets	5.50	3.09
f Intangible Assets under development	-	-
g Biological assets other than bearer plants	-	-
h Financial Assets:		
Investments	29.66	49.14
Trade Receivables	-	-
Loans	-	-
Others	-	-
Loans	-	-
Others	-	-
i Deferred Tax Assets (net)	-	-
Other Non Current Assets	20.15	21.06
Total Non Current Assets	233.00	261.95

2 Current Assets

a Inventories	90.68	79.40
b Financial Assets	-	-
Investments	-	-
Trade Receivables	351.34	328.73
Cash and Cash Equivalents	111.78	19.93
Bank balances other than above	-	-
Loans	445.00	424.23
Others	140.40	-
c Current Tax Assets (net)	-	-
d Other Current Assets	-	219.78
Total Current Assets	1,139.21	1,072.07

Total Assets **1,372.21** **1,334.02**

EQUITY AND LIABILITIES

1 Equity

a Equity Share Capital	810.00	810.00
b Other Equity	250.29	282.05
Total - Equity	1,060.29	1,092.05

Non Controlling Interest

52.48

50.05

2 Liabilities

Non Current Liabilities

a Financial Liabilities	-	-
Borrowings	76.72	93.07
Trade Payables	-	-
Other Financial Liabilities	-	-
b Provisions	-	-
c Deferred Tax Liabilities (net)	1.90	0.23
d Other Non Current Liabilities	-	-
Total Non Current Liabilities	78.62	93.30

Current Liabilities

a Financial Liabilities	-	-
Borrowings	164.81	80.76
Trade Payables	-	-
Other Financial Liabilities	-	-
b Other Current Liabilities	13.28	7.35
c Provisions	-	-
d Current Tax Liabilities (net)	2.74	10.51
Total Current Liabilities	180.82	98.62

Total - Equity and Liabilities **1,372.21** **1,334.02**

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)

Plot No. 1/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

Email : info@trimurthidrugs.com

Website : www.trimurthidrugs.com

CIN No : L67120TG1994PLC018956

For Trimurthi Ltd

Arun Kumar Bhanqadia

Managing Director

Din No. 00021024



TRIMURTHI LIMITED
SCHEDULE III OF THE COMPANIES ACT 2013
CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER IV AND 12 MONTHS ENDED 31ST MARCH, 2020



PART-I

(Amount in lakhs Except EPS)

Particulars	Quarter Ended			Year Ended	
	31-03-2020	31-12-2019	31-03-2019	31-03-2020	31-03-2019
	Audited	Unaudited	Audited	Audited	Audited
I. Income From Operations					
Net Sales / Income from Operations	266.24	252.26	255.39	1024.44	1045.92
Other Income	21.30	14.38	34.93	60.11	37.73
II. Total Income	287.54	266.64	290.32	1084.55	1083.65
III. Expenses					
a. Consumption of Raw Material	(9.27)	154.05	28.81	211.84	154.21
b. Purchase of Traded Goods/Shares	140.81	119.11	146.71	552.25	594.28
c. (Increase)/Decrease in stock in trade and work in Progress	(2.90)	3.30	19.23	(9.45)	1.95
d. Manufacturing Expenses	104.35	(45.92)	36.86	162.05	153.86
e. Employee benefits expense	23.04	24.97	22.95	96.49	98.62
f. Rent	2.25	1.50	1.95	6.75	7.80
g. Finance Cost	2.07	3.01	3.36	11.45	12.97
h. Depreciation	4.01	5.07	5.77	19.14	21.25
i. Other Expenditure	18.66	11.50	10.37	55.52	51.12
Total	283.02	276.60	276.00	1106.04	1096.05
IV. Profit/ (Loss) before Exceptional and Tax (II-III)	4.52	(9.95)	14.32	(21.50)	(12.40)
V. Exceptional Items/Prior Period Items					
VI. Profit/ (Loss) before tax (IV-V)	4.52	(9.95)	14.32	(21.50)	(12.40)
VII. Tax expense:					
(1) Current tax	0.87	0.65	5.09	2.74	10.51
(2) Deferred tax	0.53	0.21	0.34	1.68	(8.12)
VIII. Net Profit/ (Loss) for the period from continuing operations (VI-VII)	3.12	(10.81)	8.89	(25.91)	(14.79)
IX. Profit/loss) from discontinued operations	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
X. Tax expenses of discontinued operations	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XI. Profit/(loss) from Discontinued operations (after tax) (IX-X)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XII. Profit/(loss) for the period (VIII+XI)	3.12	(10.81)	8.89	(25.91)	(14.79)
XIII. Other Comprehensive Income					
A. (i) Items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
B. (i) Items that will be reclassified to profit or loss	(2.01)	(0.19)	9.76	(3.43)	(0.43)
(ii) Income tax relating to items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XIV. Total Comprehensive Income for the period (XII+XIII)Comprising Profit (Loss) and Other comprehensive Income for the period)	1.11	(11.00)	18.65	(29.34)	(15.21)
XV. Minority Interest	0.28	0.92	3.91	2.43	9.40
XVI. Total Comprehensive Income for the period after Minority Interest (XIV-XV)	0.83	(11.93)	14.74	(31.76)	(24.62)
XVII. Earnings per equity share (for continuing operation):					
(1) Basic	0.04	(0.14)	0.06	(0.35)	(0.30)
(2) Diluted	0.04	(0.14)	0.06	(0.35)	(0.30)
XVIII. Earnings per equity share (for discontinuing operation):					
(1) Basic	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(2) Diluted	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XIX. Earnings per equity share (for discontinuing & continuing operation):					
(1) Basic	0.04	(0.14)	0.06	(0.35)	(0.30)
(2) Diluted	0.04	(0.14)	0.06	(0.35)	(0.30)



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED
SCHEDULE III OF THE COMPANIES ACT 2013

PART-II



Particulars	Quarter Ended			Year Ended	
	31-03-2020	31-12-2019	31-03-2019	31-03-2020	31-03-2019
	Audited	Unaudited	Audited	Audited	Audited
A. Particulars Of Share Holding					
1. Public Share Holding					
- Number of Shares	2900600	2900600	2900600	2900600	2900600
- Percentage of shareholding	35.81%	35.81%	35.18%	35.81%	35.81%
2. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	-Nil-	-Nil-	-Nil-	-Nil-	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	-Nil-	-Nil-	-Nil-	-Nil-	Nil
- Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-	-Nil-	-Nil-	Nil
b. Non encumbered					
- No of Equity Shares	5199400	5199400	5199400	5199400	5199400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	64.19%

Particulars	3 Months Ended (31/03/2020)
B. Investor Complaints	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

Segment Reporting

Particulars	Quarter Ended			Year Ended	
	31-03-2020	31-12-2019	31-03-2019	31-03-2020	31-03-2019
	Audited	Unaudited	Audited	Audited	Audited
1. Segment Revenue					
a. Pharma Business	259.25	124.46	182.68	663.56	663.56
b. Financial Services	24.43	13.08	12.83	57.78	57.78
c. Investments	7.98	1.23	11.14	12.99	12.99
d. Foods	16.80	109.46	73.69	318.51	318.51
e. Trading in Shares	(21.81)	18.41	9.98	30.81	30.81
Total	286.64	266.64	290.32	1083.65	1083.65
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Net Sales/ Income From Operations	286.64	266.64	290.32	1083.65	1083.65
2. Segment Profits (Before tax & Interest From Each Segment)					
a. Pharma Business	16.67	2.19	5.02	23.20	23.20
b. Financial Services	(0.73)	13.08	5.56	32.62	32.62
c. Investments	7.98	1.23	11.14	12.99	12.99
d. Foods	(69.76)	(13.20)	(12.20)	(95.19)	(95.19)
e. Trading in Shares	59.45	(13.25)	4.81	13.97	13.97
Total	13.62	(9.95)	14.32	(12.40)	(12.40)
Less:					
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Total Profit Before Tax	13.62	(9.95)	14.32	(12.40)	(12.40)
3. Capital Employed					
a. Pharma Business	75.39	74.99	85.41	75.39	85.41
b. Financial Services	367.98	369.90	453.22	367.98	453.22
c. Investments	23.18	30.19	49.14	23.18	49.14
d. Foods	107.31	123.41	190.67	107.31	190.67
e. Trading in Shares	486.44	460.97	313.62	486.44	313.62
Total	1060.29	1059.46	1092.06	1060.29	1092.06

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956



Notes:

- 1 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 2 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 18-06-2020
- 3 The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs, Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter ended 31st March, 2020. The Ind-AS Complaint figures for the Corresponding previous Quarter ended 31st March, 2019 have not been subject to review or audit, however the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- 4 The results are also available on the website of the Company

Place : Hyderabad

Date : 18-06-2020



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956



P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

TO
THE BOARD OF DIRECTORS OF
TRIMURTHI LIMITED

Report on the audit of the Standalone Financial Results

Opinion:

We have audited the accompanying standalone quarterly financial results of M/s. Trimurthi Limited for the quarter ended 31st March, 2020 and the year to date results for the period from 01-04-2019 TO 31-03-2020, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31st March, 2020 as well as the year to date results for the period from 01-04-2019 to 31-03-2020.

Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

~ee~



P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA.
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.





P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082, INDIA

Tel : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For P. Murali & Co,
Chartered Accountants,
FRN No: 007257S



A Krishna Rao
Partner
M.No:020085
UDIN:20020085AAAAAFW15409

Place: Hyderabad
Date: June 18, 2020



P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

INDEPENDENT AUDITOR'S REPORT

THE BOARD OF DIRECTORS OF TRIMURTHILIMITED

Report on the audit of the Consolidated Financial Results

We have audited the accompanying Statement of Consolidated Financial Results of M/s Trimurthi ("Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group") for the quarter ended 31st March 2020 and for the period from 01-04-2019 to 31-03-2020 ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31st March 2020 and the corresponding period from 01-04-2019 to 31-03-2020, as reported in these financial results have been approved by the holding company's Board of Directors, but have not been subjected to audit/review

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports on separate financial statements/ financial information of subsidiaries, the Statement:

- a. includes the results of the following entity:
 - i) Trimurthi Foods Limited
 - ii) Trimurthi Pharmaceuticals (INDIA) Private Limited.
- b. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- c. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income (comprising of net profit and other comprehensive income) and other financial information of the Group for the quarter ended 31st March 2020 and for the period from 01-04-2019 to 31-03-2020.





Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

These quarterly financial results as well as the year to date consolidated financial results have been prepared on the basis of the interim financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listed Companies Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.





P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and of its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Other Matters

Based on our audit conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co,
Chartered Accountants,
FRN No: 007257S

A Krishna Rao
Partner
M.No:020085
UDIN:20020085AAAAAFX 2579

Place: Hyderabad
Date: June 18, 2020

Date: 18.06.2020

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai- 400 001

Sub: Declaration in respect of Audit Report with an Un-modified opinion for the Financial Year ended March 31, 2020

Dear Sir/ Madam,

With Reference to the Subject Cited, whereby we submitted Form A for the Audit Report on the Financial Results in accordance with Regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as applicable on that date.

In addition to the above and pursuant to SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016; we hereby give a declaration that the Statutory Auditors - M/s. P. Murali & Co., Chartered Accountants, have submitted their Audit Report for the year ended March 31, 2020 with an Un-modified opinion.

Request you take the same on records.

Thanking you
For TRIMURTHI LIMITED

Arun Kumar Bhangadia
Managing Director
DIN: 0002102

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

Compliance under Regulation 33 of Securities and Exchange Board Of India (Listing Obligations and Disclosure Requirements) Requirements, 2015

FORM A
Annual Audit Report

1. Name of the company	Trimurti Limited
2. Annual financial statements for year ended	31 March 2020 (Board Meeting held on Thursday 18/06/2020)
3. Type of Audit observation	On - Co. died
4. Frequency of observation	Not Applicable
5. To be signed by:	Arun Kumar Bhangadia, Managing Director (DIN: 00021024) Managing Director

Review done
18/06/2020

Chief Financial Officer (CFO)

VANIL MANDA (PAN No: AMPPV9380F)

VANIL

Statutory Auditor of the Company

M/s P Murali & Co
Chartered Accountants FRN: 0072575
A Krishna Rao
Partner M. No: 020085

P. Murali



Chairman of Audit Committee

Mr. Sagar Raviendra Karwa (DIN: 07535660)

S. Karwa